These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 24824662

  • 1. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study.
    Stryjer R, Budnik D, Ebert T, Green T, Polak L, Weizman S, Spivak B.
    Clin Neuropharmacol; 2014; 37(3):79-81. PubMed ID: 24824662
    [Abstract] [Full Text] [Related]

  • 2. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
    Stryjer R, Dambinsky Y, Timinsky I, Green T, Kotler M, Weizman A, Spivak B.
    Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
    [Abstract] [Full Text] [Related]

  • 3. Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.
    Rutrick D, Stein DJ, Subramanian G, Smith B, Fava M, Hasler G, Cha JH, Gasparini F, Donchev T, Ocwieja M, Johns D, Gomez-Mancilla B.
    Adv Ther; 2017 Feb; 34(2):524-541. PubMed ID: 28044255
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM, Aboujaoude E, Gamel NN.
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [Abstract] [Full Text] [Related]

  • 6. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S, Mokhtari S, Shariat SV, Shariati B, Yarahmadi M, Shalbafan M.
    BMC Psychiatry; 2022 Jan 12; 22(1):34. PubMed ID: 35022014
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
    Tzavellas E, Karaiskos D, Ilias I, Liappas I, Paparrigopoulos T.
    Psychiatriki; 2014 Jan 12; 25(3):179-84. PubMed ID: 25367661
    [Abstract] [Full Text] [Related]

  • 9. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG.
    J Clin Psychiatry; 2017 Jul 12; 78(7):e766-e773. PubMed ID: 28617566
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM, Ringold AL, Elliott MA.
    J Clin Psychiatry; 2000 Jul 12; 61(7):514-7. PubMed ID: 10937610
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S.
    J Clin Psychiatry; 2004 Apr 12; 65(4):565-8. PubMed ID: 15119922
    [Abstract] [Full Text] [Related]

  • 16. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H, Jia F, Han H, Wang S, Guo G, Quan D, Li G, Huang H.
    Eur Neuropsychopharmacol; 2019 Mar 12; 29(3):397-404. PubMed ID: 30595354
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of Ziprasidone Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 12-Week, Open-Label Uncontrolled Preliminary Study.
    Bruno A, Pandolfo G, Cedro C, Gallo G, De Felice M, Zoccali RA, Muscatello MR.
    Clin Neuropharmacol; 2016 Mar 12; 39(1):6-9. PubMed ID: 26757309
    [Abstract] [Full Text] [Related]

  • 19. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E.
    CNS Drugs; 2009 Dec 12; 23(12):1047-55. PubMed ID: 19958042
    [Abstract] [Full Text] [Related]

  • 20. L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
    Nematizadeh M, Ghorbanzadeh H, Moghaddam HS, Shalbafan M, Boroon M, Keshavarz-Akhlaghi AA, Akhondzadeh S.
    Psychiatry Clin Neurosci; 2023 Sep 12; 77(9):478-485. PubMed ID: 37169515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.